September 7, 2005 -- Alnylam and Novartis signed a major partnership that sends $56.8 million to Alnylam now and includes another $700 million in milestones, GlaxoSmithKline increased its vaccine portfolio by buying ID Biomedical, Bristol-Myers Squibb won the approval of an FDA panel yesterday for its rheumatoid arthritis treatment, Ista Pharma released positive data from a Phase III trial of a drug for vitreous hemorrhage, Genentech said its TNKase clot-breaking drug can not be used with angioplasty, and the company also announced that Lucentis did now win fast-track status. The Centient Biotech 200™ was off 12 points at 3906.14, a loss of .32%. More details...
